Related Experiment Videos
Optimal cyclosporine therapy--an Indian experience
The Journal of the Association of Physicians of India
|January 1, 1996
Summary
Renal transplant patients on triple immunosuppression showed stable cyclosporine blood levels despite dose reduction, indicating effective management. This suggests optimized dosing strategies may reduce rejection risk.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Renal transplantation is a vital treatment for end-stage renal disease.
- Maintaining adequate immunosuppression while minimizing toxicity is crucial post-transplant.
- Cyclosporine, azathioprine, and prednisolone form a common triple immunosuppression regimen.
Purpose of the Study:
- To prospectively evaluate the efficacy and safety of a cyclosporine-based immunosuppression protocol in adult renal transplant recipients.
- To monitor cyclosporine blood levels and renal function during a 6-month follow-up period.
- To assess the relationship between cyclosporine dosage adjustments and patient outcomes.
Main Methods:
- Prospective study of 30 adult renal transplant patients.
- Administered triple immunosuppression: cyclosporine (initial dose 7 mg/kg/day), azathioprine, and prednisolone.
- Monitored oral cyclosporine (CyA) blood levels using monoclonal RIA (Cyclo-Trac-NS) at multiple time points (days 3, 10, 30, 60, 90, 180).
- Titrated CyA dose based on blood levels and renal function, with a monthly dose reduction of 1 mg/kg.
Main Results:
- Despite a progressive dose reduction of CyA, blood levels remained stable, suggesting increased absorption or decreased metabolism.
- Significant changes in CyA dose did not lead to significant alterations in CyA blood levels or serum creatinine.
- Patients achieved optimal blood CyA levels (387-2120 ng/dL) with relatively lower doses.
- No evidence of graft rejection or irreversible nephrotoxicity was observed during the study period.
Conclusions:
- A cyclosporine-based triple immunosuppression regimen can maintain stable therapeutic drug levels in renal transplant patients, even with dose reduction.
- The observed stability in CyA levels may be attributed to pharmacokinetic factors like enhanced absorption or reduced metabolism.
- This dosing strategy appears safe and effective, requiring lower doses to achieve optimal blood levels and preventing rejection or nephrotoxicity.